TRIMEDX Receives International Organization for Standardization’s Highly Regarded Quality Management System Recertification

TRIMEDX―an industry-leading, independent clinical asset management company delivering clinical engineering services, clinical asset informatics, and medical device cybersecurity―has been recertified with the highly regarded International Organization for Standardization’s Medical Device Quality Management System (MD QMS) certification ISO 13485, a widely recognized international standard outlining best practices in developing an effective MD QMS that covers the safety and quality of medical devices throughout their lifecycle.

This recertification, now valid through Aug. 2027, reverifies that TRIMEDX continues its dedication to maintaining a comprehensive quality management system (business policies and procedures), ultimately impacting its service excellence to clients.

“This reaffirms our commitment to excellence for our clients, associates, and stakeholders,” says TRIMEDX CEO Henry Hummel. “Our quality of service standardizes work and contributes to continuous improvement as we progress. By verifying these processes, we aim to achieve best-in-class customer satisfaction, quality service, and ultimately impact clients’ ability to ensure patient safety.”

This standard analyzes and evaluates everything TRIMEDX does from a risk perspective, so risk control is included in all parts of the business. ISO 13485 outlines best practices in developing an effective MD QMS that covers the safety and quality of medical devices throughout their lifecycle. TRIMEDX was recertified by third-party registrar DEKRA.
The ISO 13485 certification couples with TRIMEDX’s Service Organization Control (SOC) 2 Type 2 and ISO 27001 certification (valid through Dec. 2026) to make up TRIMEDX’s Quality Management System covering MD QMS and Information Security Management System (ISMS) standards.

“Achieving this level of compliance requires a continued commitment and demonstrated ability to monitor system activity and quickly take corrective action with the people, process, and technology in place,” says Denisa Lambert, vice president of quality & regulatory compliance. “Our comprehensive approach to data protection and responsive action sets us apart in delivering service excellence to clients.”

SourceTRIMEDX

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version